| |
|
jSLE(n=33)n(%) |
aSLE(n=32)n(%) |
Total(n=65) |
P value |
| Sex n (%) |
Female |
28(84.8) |
31(96.9) |
59(90.8) |
0.197 |
| Male |
5(15.2) |
1(3.1) |
6(9.2) |
| Mucocutaneous n (%) |
-ve |
6(18.2) |
5(15.6) |
11(16.9) |
0.783 |
| +ve |
27(81.8) |
27(84.4) |
54(83.1) |
| Muscloskeletaln(%) |
-ve |
10(30.3) |
4(12.5) |
14(21.5) |
0.081 |
| +ve |
23(69.7) |
28(87.5) |
51(78.5) |
| Serositisn(%) |
-ve |
21(63.6) |
21(65.6) |
42(64.6) |
0.867 |
| +ve |
12(36.4) |
11(34.4) |
23(35.4) |
| Cardiac n(%) |
-ve |
22(66.7) |
14(43.8) |
36(55.4) |
0.063 |
| +ve |
11(33.3) |
18(56.3) |
29(44.6) |
| Chest n(%) |
-ve |
30(90.9) |
26(81.3) |
56(86.2) |
0.303 |
| +ve |
3(9.1) |
6(18.8) |
9(13.8) |
| Lupus nephritis n(%) |
-ve |
12(36.4) |
11(34.4) |
23(35.4) |
0.867 |
| +ve |
21(63.6) |
21(65.6) |
42(64.6) |
| Lupus cerebritisn(%) |
-ve |
24(72.7) |
22(68.8) |
46(70.8) |
0.724 |
| +ve |
9(27.3) |
10(31.3) |
19(29.2) |
| Hematological n(%) |
-ve |
16(48.5) |
15(46.9) |
31(47.7) |
0.897 |
| +ve |
17(51.5) |
17(53.1) |
34(52.3) |
| ANA n(%) |
-ve |
7(21.2) |
5(15.6) |
12(18.5) |
0.562 |
| +ve |
26(78.8) |
27(84.4) |
53(81.5) |
| dsDNA n(%) |
-ve |
20(60.6) |
13(40.6) |
33(50.8) |
0.107 |
| +ve |
13(39.4) |
19(59.4) |
32(49.2) |
|
| *P is only statistically significant if ≤ 0.05. |
| Table 1: The clinical and laboratory characteristics among patients with juvenile
and adult SLE. |
